Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial.

988 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? (2008, background): “trolled trials have consistently shown no survival benefit from multiple new treatment strategies, such as increased dialysis dose (2,3), intensified nutrition (4), homocysteine-lowering therapy (5), normalization of hemoglobin with erythropoietin (6,7), lipid lowering with statins (8), and treatmen”
IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly. (2005, result): “However, the recent HEMO [3] and ADEMEX [4] studies indicate that increased small solute clearances over and above those applied in current clinical practice do not necessarily result in improved survival, thus indicating that “dialysis adequacy” is more than Kt/V urea.”
Survival advantages of obesity in dialysis patients. (2005, background): “ing the HEMO (3) and ADAMEX (4) studies, failed to show any”